Diaceutics (LON:DXRX) Reaches New 12-Month High – Still a Buy?

Diaceutics PLC (LON:DXRX)’s stock price reached a new 52-week high on Thursday . The company traded as high as GBX 180 and last traded at GBX 180, with a volume of 246222 shares trading hands. The stock had previously closed at GBX 174.

Analyst Upgrades and Downgrades

Separately, Shore Capital Group increased their price target on Diaceutics from GBX 180 to GBX 215 and gave the company a “buy” rating in a research report on Thursday, January 15th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of GBX 193.33.

Diaceutics Price Performance

The stock has a 50-day moving average of GBX 155.89 and a two-hundred day moving average of GBX 153.88. The firm has a market cap of £148.95 million, a price-to-earnings ratio of -97.78 and a beta of 0.92. The company has a current ratio of 3.96, a quick ratio of 9.92 and a debt-to-equity ratio of 3.05.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.